MT1M (Metallothionein 1M)

Our study establishes MRGs, particularly the core genes MT1M and MT1X, as crucial players in BC heterogeneity and pathogenesis. They serve as promising diagnostic biomarkers and potential therapeutic targets, with their tumor-suppressive roles likely mediated through the modulation of key oncogenic signaling pathways.

MT1M, GRHL2, and PKM are novel diagnostic and therapeutic targets for breast cancer. These findings enhance prognostic evaluations, deepen our understanding of its mechanisms.

This study demonstrated that aloin activates the NR3C2/MT1M axis to suppress the malignant behavior of LUSC cells and M2 macrophage polarization. Please cite this article as: Chen YN, Lu JY, Gao CF, Fang ZR, Zhou Y. Aloin blocks the malignant behavior of lung squamous cell carcinoma cells and M2 macrophage polarization by modulating the NR3C2/MT1M axis. J Integr Med. 2025; Epub ahead of print.

This research indicates that the aberrant hypermethylation and low expression of LINC00261 were associated with platinum resistance and adverse outcomes in EOC patients.

Decreased expression of MT1M was associated with worse clinical prognosis, particularly in patients treated with 5-fluorouracil...Furthermore, we found that MT1M overexpression could inhibit stem cell characteristics by targeting GLI1 and affecting GLI1 ubiquitination. Collectively, these findings indicated that MT1M may act as a tumor suppressor in GC and could serve as a potential therapeutic target to attenuate stemness and chemotherapy resistance of GC.